Azenta Inc
NASDAQ:AZTA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Azenta Inc
Free Cash Flow
Azenta Inc
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Azenta Inc
NASDAQ:AZTA
|
Free Cash Flow
$30.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
24%
|
CAGR 10-Years
11%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Free Cash Flow
$6.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
10%
|
|
|
Danaher Corp
NYSE:DHR
|
Free Cash Flow
$5.3B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
4%
|
|
|
Waters Corp
NYSE:WAT
|
Free Cash Flow
$539.8m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
1%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Free Cash Flow
$993m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
6%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Free Cash Flow
$2.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
18%
|
|
Azenta Inc
Glance View
Azenta Inc. emerged as a focused entity after the strategic divestiture of Brooks Automation's semiconductor business, carving out a niche to serve the life sciences industry with precision. The company's evolution is a testament to its strategic agility, aligning itself with the burgeoning demand for data-driven decision-making in healthcare and biotechnology. Azenta specializes in providing comprehensive solutions that revolve around sample management, genomic services, and automated storage systems. By ensuring the integrity and accessibility of biological samples and data, Azenta plays a crucial role in accelerating research and development processes. Its core operations are built upon intricate platforms that manage critical laboratory activities and genomic sequencing, enabling laboratories and research institutions to streamline their workflows and enhance productivity. Central to Azenta's business model is its recurring revenue stream derived from life science products and services, which supports labs in safeguarding and optimizing essential research materials. The company's offerings encompass robust automated systems, state-of-the-art genomic services, and logistics that ensure seamless sample management from collection to analysis. Through strategic partnerships and continuous innovation, Azenta effectively supports its clients in navigating the complexities of modern research, ultimately helping translate scientific endeavors into tangible outcomes. By continually expanding its technological capabilities and service offerings, Azenta not only fortifies its market position but also underscores its commitment to facilitating transformative advancements in life science and healthcare industries.
See Also
What is Azenta Inc's Free Cash Flow?
Free Cash Flow
30.9m
USD
Based on the financial report for Dec 31, 2025, Azenta Inc's Free Cash Flow amounts to 30.9m USD.
What is Azenta Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
11%
Over the last year, the Free Cash Flow growth was 51%.